The AI‑designed vaccine that could stop the next pandemic successfully passes its first human trial

A new type of universal vaccine has successfully completed its first human trial, marking a major step toward a technology that could prevent future pandemics before they emerge. Developed by researchers at the University of Cambridge and its spinout company, DIOSynVax, the experimental vaccine was found to be safe and produced no serious side effects in a study involving 39 healthy volunteers.

Unlike current vaccines, which target specific strains, this vaccine is designed to provide protection against multiple variants with a single dose. More specifically, it targets the sarbecovirus family of coronaviruses. This group includes SARS-CoV-2, the virus responsible for COVID-19, the original SARS virus, and several related viruses. The trial confirmed that participants developed immune defenses against all of them.

A computer-designed “super antigen”

The study represents a significant scientific breakthrough because it is the first time a vaccine whose active component was designed entirely by a computer has been tested in humans.

To achieve this, scientists analyzed all available genetic data on these coronaviruses from databases around the world. Using artificial intelligence, the system identified the features shared across the entire virus family and designed a single “super antigen.” The goal is to train the immune system to defend not only against known viruses, but also against future mutations that have not yet emerged. The same technology could potentially be used to provide long-lasting protection against other major threats, including the Ebola virus family.

“Like a dog chasing its tail”

Many current vaccines, including seasonal flu and covid-19 vaccines, are developed based on strains or variants that have already been identified in humans. The challenge is that viruses are constantly evolving. As a result, these vaccines offer limited long-term protection and often need to be updated each year to remain effective.

According to Professor Jonathan Heeney, the study’s lead scientist, this new approach could fundamentally change the traditional vaccine-development model. He explained that the goal is to create vaccines that are prepared for future threats rather than simply reacting after those threats appear, a process he vividly compared to “a dog chasing its tail.”

Needle-free delivery and next steps

Volunteers between the ages of 18 and 50 received the vaccine at NIHR clinical research facilities in Southampton and Cambridge. The study was sponsored by Southampton University Hospital, and the findings were published in the Journal of Infection.

Another notable feature of the vaccine is how it is administered. Instead of using a conventional needle, it is delivered through a microfluidic jet device that uses pressurized fluid. This approach eliminates injections altogether. It may be especially appealing to people with needle anxiety and could also make large-scale vaccination campaigns faster and easier to implement.

Although earlier animal studies and this first human trial have produced encouraging results, additional development is still required before the vaccine can receive regulatory approval. The next step will be a larger Phase 2 clinical trial designed to confirm its effectiveness in a broader and more diverse population.

As Professor Saul Faust noted, viruses continue to evolve at a rapid pace, and current systems often struggle to keep up. That is why he emphasized the potential of this technology, which received funding from Innovate UK, the United Kingdom’s national innovation agency. According to Faust, “millions of lives could be saved, lockdowns avoided and the economy preserved.”

Get closer to the game! Whether you like your soccer of the European variety or that on this side of the pond, our AS USA app has it all. Dive into live coverage, expert insights, breaking news, exclusive videos, and more. Plus, stay updated on NFL, NBA and all other big sports stories as well as the latest in current affairs and entertainment. Download now for all-access coverage, right at your fingertips – anytime, anywhere.

And there’s more: check out our TikTok and Instagram reels for bite-sized visual takes on all the biggest soccer news and insights.